Sander is Managing Partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion in 2006.
Sander currently serves on the boards of Forbion portfolio companies NorthSea Therapeutics (Chair) and Azafaros. Until recently, Sander chaired the boards of NewAmsterdam Pharma (Nasdaq: NAMS) and Forbion European Acquisition Corp (Nasdaq: FRBN) and served on the boards of Replimune (Nasdaq: REPL) and uniQure (Nasdaq: QURE) and is responsible for numerous high value exits at Forbion. Sander is a member of all investment committees at both Forbion and BGV and as such is also involved with Forbion’s BioEconomy strategy. In addition, Sander has been a member of the board of the private markets industry body Invest Europe and chairs its Venture Council.
Before co-founding Forbion in 2006, he had been a co-founder of ABN AMRO Capital/Life Sciences back in 2000. His other activities at ABN AMRO Bank included buy-out/ growth equities investments at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).
Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nyenrode University, The Netherlands.
Investing in the LS space can be very rewarding as financial success is often coupled to success for patients in new drugs and devices for high needs reaching the markets.
Portfolio
Companies worked on by Sander Slootweg
